COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00030667
Recruitment Status : Completed
First Posted : May 7, 2003
Last Update Posted : April 15, 2015
Information provided by (Responsible Party):
National Cancer Institute (NCI)

Brief Summary:
Phase II trial to study the effectiveness of imatinib mesylate in treating patients who have relapsed or refractory solid tumors of childhood. Imatinib mesylate may stop the growth of tumor cells by blocking the enzymes necessary for their growth.

Condition or disease Intervention/treatment Phase
Childhood Desmoplastic Small Round Cell Tumor Childhood Synovial Sarcoma Gastrointestinal Stromal Tumor Lung Metastases Recurrent Childhood Soft Tissue Sarcoma Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor Recurrent Neuroblastoma Recurrent Osteosarcoma Drug: imatinib mesylate Other: laboratory biomarker analysis Other: pharmacological study Phase 2

Detailed Description:


I. Determine the response rate of patients with relapsed or refractory pediatric solid tumors treated with imatinib mesylate.

II. Determine the toxicity of this drug in these patients. III. Determine the time to progression in patients treated with this drug. IV. Determine the pharmacokinetics of this drug in these patients. V. Correlate response with c-kit and platelet-derived growth factor receptor expression in patients treated with this drug.

OUTLINE: This is a multicenter study. Patients are stratified according to disease (Ewing's sarcoma/primitive neuroectodermal tumor vs osteosarcoma vs neuroblastoma vs other).

Patients receive oral imatinib mesylate once or twice daily on days 1-28. Courses repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 100 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Study of Gleevec (Imatinib Mesylate, NSC 716051 Formerly STI571) in Children With Refractory or Relapsed Solid Tumors
Study Start Date : May 2002
Actual Primary Completion Date : December 2005
Actual Study Completion Date : December 2005

Arm Intervention/treatment
Experimental: Treatment (imatinib mesylate)
Patients receive oral imatinib mesylate once or twice daily on days 1-28. Courses repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
Drug: imatinib mesylate
Given orally
Other Names:
  • CGP 57148
  • Gleevec
  • Glivec

Other: laboratory biomarker analysis
Correlative studies

Other: pharmacological study
Correlative studies
Other Name: pharmacological studies

Primary Outcome Measures :
  1. Response rate, determined using the RECIST criteria [ Time Frame: Up to 2 years ]
    95% confidence interval will be computed.

  2. Toxicity reported using the CTC version 2.0 [ Time Frame: Up to 2 years ]

Secondary Outcome Measures :
  1. Time to disease progression [ Time Frame: Up to 2 years ]
    Calculated by the method of Kaplan and Meier.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   up to 30 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically confirmed solid tumors including the following:

    • Ewing's sarcoma
    • Bone or soft tissue primitive neuroectodermal tumor
    • Osteosarcoma
    • Neuroblastoma
    • Desmoplastic small round cell tumor
    • Synovial cell sarcoma
    • Gastrointestinal stromal tumor (GIST)
  • Metastatic pulmonary disease eligible

    • No pleural effusion of any size or definite radiologic evidence of pleural-based disease
  • Recurrent or refractory to conventional therapy

    • GIST eligible at initial presentation
  • Tumor tissue blocks must be available
  • At least 1 measurable lesion

    • At least 20 mm by conventional techniques
    • At least 10 mm by spiral CT scan
    • Lesions assessable only by radionuclide scan are not considered measurable
  • Performance status - Lansky 50-100% (≤ 10 years of age)
  • Performance status - Karnofsky 50-100% (> 10 years of age)
  • At least 2 months
  • Absolute neutrophil count ≥ 1,000/mm^3*
  • Platelet count ≥ 75,000/mm^3* (transfusion independent)
  • Hemoglobin ≥ 8.0 g/dL* (RBC transfusions allowed)
  • Bilirubin ≤ 1.5 times upper limit of normal (ULN)
  • ALT ≤ 2.5 times ULN
  • INR < 1.5
  • PTT ≤ ULN
  • Fibrinogen ≥ lower limit of normal
  • Creatinine normal for age
  • Glomerular filtration rate ≥ 70 mL/min
  • No uncontrolled infection
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective barrier contraception
  • At least 1 week since prior biologic therapy or immunotherapy and recovered
  • At least 1 week since prior growth factors
  • No concurrent immunomodulating agents
  • At least 2 weeks since prior myelosuppressive chemotherapy (4 weeks for nitrosoureas) and recovered
  • No concurrent chemotherapy
  • No concurrent steroids
  • Recovered from prior radiotherapy
  • At least 2 weeks since prior local palliative radiotherapy (small port)
  • At least 3 months since prior craniospinal radiotherapy or radiotherapy to 50% or more of pelvis
  • At least 6 weeks since other prior substantial bone marrow radiation
  • No concurrent radiotherapy during first course of treatment
  • Concurrent palliative radiotherapy to local painful lesions allowed after first course of treatment provided there is no evidence of disease progression and at least 1 measurable lesion remains outside radiation port
  • No concurrent therapeutic doses of warfarin
  • No concurrent anticonvulsants that induce the cytochrome p450 enzyme system (e.g., phenytoin, carbamazepine, and phenobarbital)
  • Concurrent benzodiazepines and gabapentin allowed
  • Concurrent low-molecular weight heparin allowed

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00030667

Layout table for location information
United States, California
Children's Oncology Group
Arcadia, California, United States, 91006-3776
Sponsors and Collaborators
National Cancer Institute (NCI)
Layout table for investigator information
Principal Investigator: Mason Bond Children's Oncology Group

Layout table for additonal information
Responsible Party: National Cancer Institute (NCI) Identifier: NCT00030667    
Other Study ID Numbers: NCI-2012-01869
NCI-2012-01869 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
ADVL0122 ( Other Identifier: Children's Oncology Group )
ADVL0122 ( Other Identifier: CTEP )
U10CA098543 ( U.S. NIH Grant/Contract )
First Posted: May 7, 2003    Key Record Dates
Last Update Posted: April 15, 2015
Last Verified: December 2013
Additional relevant MeSH terms:
Layout table for MeSH terms
Gastrointestinal Stromal Tumors
Sarcoma, Ewing
Neuroectodermal Tumors
Neuroectodermal Tumors, Primitive
Neuroectodermal Tumors, Primitive, Peripheral
Sarcoma, Synovial
Desmoplastic Small Round Cell Tumor
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Neoplasms, Neuroepithelial
Neoplasms, Germ Cell and Embryonal
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Neoplasms, Bone Tissue
Neoplasms, Connective Tissue
Gastrointestinal Neoplasms
Digestive System Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Imatinib Mesylate
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action